Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 11/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469200 | 1.00 | C5AR1 (0.45) | C5AR1OPRD1MAPK1P2RX3OPRL1 | |
| SCHEMBL25576131 | 1.00 | C5AR1 (0.45) | C5AR1OPRD1MAPK1P2RX3OPRL1 | |
| SCHEMBL30469182 | 1.00 | C5AR1 (0.45) | C5AR1OPRD1MAPK1P2RX3OPRL1 | |
| SCHEMBL25576129 | 1.00 | C5AR1 (0.45) | C5AR1OPRD1MAPK1P2RX3OPRL1 | |
| SCHEMBL30469180 | 1.00 | C5AR1 (0.45) | C5AR1OPRD1MAPK1P2RX3OPRL1 | |
| SCHEMBL25236450 | 0.87 | C5AR1 (0.41) | C5AR1OPRD1P2RX3OPRL1 | |
| SCHEMBL25236451 | 0.87 | C5AR1 (0.41) | C5AR1OPRD1P2RX3OPRL1 | |
| SCHEMBL25213573 | 0.87 | C5AR1 (0.41) | C5AR1OPRD1P2RX3OPRL1 | |
| SCHEMBL25218889 | 0.80 | TRPV3 (0.38) | C5AR1OPRD1OPRL1PDE10A | |
| SCHEMBL31067853 | 0.80 | TRPV3 (0.38) | C5AR1OPRD1OPRL1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-118510783-A | Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | C5AR1 2709/4885OPRD1 3074/4885MAPK1 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.